Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech Mergers In 2001 Whet Investor Appetites: Is Gilead Next?

Executive Summary

Gilead Sciences may be the next biotech company to switch from product success story to acquisition target

You may also be interested in...



Genentech Tarceva Trials “On Track” Despite INTACT: Response To Iressa

Genentech and OSI Pharmaceuticals are pointing to the dosing regimen in clinical trials of Tarceva (erlotinib) as one reason that Phase III studies of the EGFR oncologic agent will have a positive outcome despite the negative findings in AstraZeneca's Phase III program for Iressa

Genentech Tarceva Trials “On Track” Despite INTACT: Response To Iressa

Genentech and OSI Pharmaceuticals are pointing to the dosing regimen in clinical trials of Tarceva (erlotinib) as one reason that Phase III studies of the EGFR oncologic agent will have a positive outcome despite the negative findings in AstraZeneca's Phase III program for Iressa

GlaxoSmithKline Is Mouthful But Still Hungry: Is Next Course Japanese?

GlaxoSmithKline's acquisition strategy will concentrate on medium-sized pharmaceutical and biotech companies with a pipeline, CEO J.P. Garnier told analysts during a Feb. 22 meeting in London.

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel